Cholesterol-Lowering Antibody Evolocumab Cuts Heart Attack Risk in Landmark Analysis
A meta-analysis of nine randomised trials involving nearly 68,000 patients shows evolocumab dramatically lowers LDL cholesterol and reduces heart attacks ...
Tag: PCSK9 inhibitor
POPULAR NEWS
-
Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone
-
Endurance Exercise Reshapes the Liver in Males and Females Through Distinct Molecular Routes
-
Single Transcription Factor PU.1 Rapidly Converts Fibroblasts into Macrophage-Lineage Cells
-
New Scale Measures How Ready Nurse Educators Really Are for the AI Era